Venn acquires Labskin animal-testing substitute
Venn Life Sciences, the clinical research organisation (CRO) based in Dublin, Ireland, has acquired for £210,000 the trading assets of dermatology company Evocutis, including the latter’s Labskin skin substitute, an alternative to animal testing for dermatology products including medicines and cosmetics.
Read More




